Shares of Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.
A number of brokerages recently weighed in on STVN. Citigroup cut their price target on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley cut their price target on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th.
View Our Latest Stock Report on Stevanato Group
Institutional Investors Weigh In On Stevanato Group
Stevanato Group Trading Down 0.2 %
NYSE STVN opened at €19.27 ($21.18) on Monday. Stevanato Group has a 1 year low of €16.56 ($18.20) and a 1 year high of €35.56 ($39.08). The company has a current ratio of 1.74, a quick ratio of 1.13 and a debt-to-equity ratio of 0.19. The company has a fifty day moving average price of €20.35 and a 200-day moving average price of €23.15.
Stevanato Group (NYSE:STVN – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.10 ($0.11) by (€0.01) (($0.01)). The firm had revenue of €259.60 million during the quarter, compared to the consensus estimate of €254.92 million. Stevanato Group had a return on equity of 10.89% and a net margin of 11.27%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.15 EPS. As a group, sell-side analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current year.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
See Also
- Five stocks we like better than Stevanato Group
- Earnings Per Share Calculator: How to Calculate EPS
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Use Stock Screeners to Find Stocks
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- 3 Warren Buffett Stocks to Buy Now
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.